Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576064 | 1.00 | BACE1 (0.52) | BACE1CTSSCTSKBACE2TSHR | |
| SCHEMBL30402961 | 0.97 | BACE1 (0.53) | BACE1CTSSCTSKBACE2TSHR | |
| SCHEMBL38660733 | 0.93 | CTSK (0.46) | BACE1CTSSCTSKFNTAFNTB | |
| SCHEMBL38662206 | 0.87 | CTSK (0.52) | CTSSCTSKFNTAFNTB | |
| SCHEMBL30402046 | 0.87 | CTSS (0.53) | BACE1CTSSCTSKTSHR | |
| SCHEMBL8931425 | 0.85 | CTSK (0.48) | CTSSCTSKTSHR | |
| SCHEMBL32681199 | 0.85 | CTSK (0.48) | CTSSCTSKTSHR | |
| SCHEMBL28058553 | 0.85 | CTSK (0.48) | CTSSCTSKTSHR | |
| SCHEMBL30349304 | 0.85 | TSHR (0.49) | BACE1CTSSCTSKBACE2TSHR | |
| SCHEMBL20332819 | 0.84 | CTSK (0.53) | BACE1CTSSCTSKFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689892-B1 | RADIOACTIVE DRUG | UNIV CHIBA NAT UNIV CORP (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11167050-B2 | Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2021-11-09 | — | — | US | disclosed |
| US-10960089-B2 | Radiolabeled drug | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2021-03-30 | — | — | US | disclosed |
| US-20200268913-A1 | RADIOACTIVE DRUG | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2020-08-27 | — | — | US | disclosed |
| EP-3689892-A1 | RADIOACTIVE DRUG | National University Corporation Chiba University (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-20190091353-A1 | RADIOLABELED DRUG | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2019-03-28 | — | — | US | disclosed |
| EP-3424940-A1 | RADIOLABELED DRUG | National University Corporation Chiba University (JP) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11167050-B2 | Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound | SLC30A6, AP1M1, SLC39A11 | BACE1 1479/4885CTSS 2845/4885CTSK 2338/4885 |
| US-20190091353-A1 | RADIOLABELED DRUG | SLC10A1, SLCO2A1, SLC30A5 | BACE1 2560/4885CTSS 1582/4885CTSK 1508/4885 |
| US-20200268913-A1 | RADIOACTIVE DRUG | TFRC, LUC7L2, MRPL19 | BACE1 1667/4885CTSS 2539/4885CTSK 2589/4885 |
| US-10960089-B2 | Radiolabeled drug | TFRC, CLINT1, SLC10A1 | BACE1 1038/4885CTSS 2222/4885CTSK 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.